Encompass Health Corporation (EHC) Key Metrics
EHC valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $12.61B
- Enterprise value
- $14.79B
- P/E (TTM)
- 21.4 10-yr median 18.0
- Forward P/E
- 18.9
- PEG ratio
- 0.41
- Price / sales
- 2.0 10-yr median 1.3
- Price / book
- 4.6 10-yr median 4.1
- EV / EBITDA
- 9.9 10-yr median 9.4
- Dividend yield
- 0.66% $0.84 a year
- Beta
- 0.60
EHC key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsEHC valuation Price multiples at each fiscal year-end price.
EHC returns How much profit the business earns on the capital it uses.
EHC per-share figures Results divided by the shares outstanding at year-end.
EHC financial health Debt, liquidity and how easily interest is covered.
EHC efficiency & capital use Working capital cycle and where the cash goes.
EHC valuation history
EHC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
EHC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
EHC cash returned to shareholders
EHC price vs earnings per share
EHC key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $10.85B | $9.44B | $6.76B | $6.00B | $5.20B | $6.57B | $5.48B | $4.90B | $3.90B | $3.26B |
| Enterprise value | $13.42B | $12.07B | $9.55B | $8.98B | $8.63B | $9.88B | $8.73B | $7.34B | $6.43B | $6.24B |
| P/E ratio | 19.2 | 20.7 | 19.2 | 22.2 | 12.6 | 23.1 | 15.3 | 16.8 | 14.4 | 13.2 |
| Price / sales | 1.8 | 1.8 | 1.4 | 1.4 | 1.3 | 1.8 | 1.2 | 1.1 | 1.0 | 0.9 |
| Price / book | 4.4 | 4.6 | 4.1 | 4.6 | 2.7 | 4.1 | 4.1 | 3.7 | 3.3 | 4.4 |
| Price / free cash flow | 24.7 | 26.2 | 25.2 | 49.3 | 31.6 | 22.1 | 23.7 | 10.0 | 9.5 | 8.1 |
| Price / operating cash flow | 9.2 | 9.4 | 7.9 | 8.5 | 7.3 | 9.3 | 8.6 | 6.4 | 5.9 | 5.4 |
| EV / sales | 2.3 | 2.2 | 2.0 | 2.1 | 2.2 | 2.8 | 1.9 | 1.7 | 1.6 | 1.7 |
| EV / EBITDA | 9.6 | 10.2 | 9.3 | 10.3 | 9.7 | 13.4 | 9.3 | 8.7 | 7.7 | 7.5 |
| EV / free cash flow | 30.5 | 33.5 | 35.7 | 73.8 | 52.5 | 33.3 | 37.8 | 14.9 | 15.6 | 15.5 |
| Earnings yield | 5.2% | 4.8% | 5.2% | 4.5% | 7.9% | 4.3% | 6.5% | 6.0% | 6.9% | 7.6% |
| Free cash flow yield | 4.0% | 3.8% | 4.0% | 2.0% | 3.2% | 4.5% | 4.2% | 10.0% | 10.6% | 12.3% |
| Dividend yield | 0.7% | 0.7% | 0.9% | 1.6% | 2.2% | 1.7% | 2.0% | 2.1% | 2.3% | 2.6% |
| Shareholder yield (dividends + buybacks) | 2.1% | 1.0% | 1.0% | 1.8% | 2.3% | 1.8% | 2.8% | 3.4% | 3.3% | 4.6% |
| Share price at fiscal year-end | $106.14 | $92.35 | $66.72 | $59.81 | $51.92 | $65.78 | $55.11 | $49.09 | $39.31 | $32.81 |
| Per share | ||||||||||
| Revenue per share | $58.07 | $52.58 | $47.40 | $43.31 | $40.07 | $35.73 | $46.33 | $42.86 | $39.41 | $36.61 |
| Earnings per share | $5.54 | $4.46 | $3.47 | $2.70 | $4.11 | $2.85 | $3.61 | $2.93 | $2.73 | $2.49 |
| Operating cash flow per share | $11.50 | $9.81 | $8.40 | $7.03 | $7.14 | $7.06 | $6.39 | $7.64 | $6.62 | $6.09 |
| Free cash flow per share | $4.30 | $3.53 | $2.64 | $1.21 | $1.64 | $2.97 | $2.33 | $4.93 | $4.15 | $4.05 |
| Cash per share | $1.42 | $0.84 | $1.40 | $0.22 | $0.49 | $2.24 | $0.95 | $0.69 | $0.55 | $0.41 |
| Book value per share | $23.86 | $20.23 | $16.26 | $13.05 | $19.07 | $15.91 | $13.60 | $13.32 | $11.90 | $7.40 |
| Tangible book value per share | $7.95 | $4.75 | $0.87 | −$2.34 | $5.15 | −$11.64 | −$14.38 | −$12.18 | −$12.02 | −$16.11 |
| Dividends per share | $0.70 | $0.61 | $0.60 | $0.99 | $1.12 | $1.12 | $1.09 | $1.01 | $0.92 | $0.84 |
| Capex per share | $7.21 | $6.29 | $5.76 | $5.82 | $5.50 | $4.09 | $4.07 | $2.71 | $2.47 | $2.04 |
| Debt per share | $26.55 | $26.55 | $28.95 | $29.80 | $34.74 | $35.50 | $33.67 | $25.19 | $25.96 | $30.32 |
| Shares outstanding | 102.2M | 102.2M | 101.3M | 100.4M | 100.2M | 99.8M | 99.4M | 99.8M | 99.3M | 99.5M |
| Change in shares outstanding | 0.0% | +0.9% | +0.9% | +0.2% | +0.4% | +0.4% | −0.4% | +0.5% | −0.2% | −1.5% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 25.1% | 24.5% | 23.8% | 16.8% | 23.6% | 19.3% | 26.8% | 23.3% | 28.3% | 36.8% |
| Return on invested capital (ROIC) | 17.3% | 15.1% | 13.1% | 10.2% | 10.3% | 11.0% | 13.1% | 13.8% | 12.4% | 11.5% |
| Return on assets (ROA) | 8.3% | 7.2% | 6.0% | 4.3% | 6.2% | 4.5% | 6.3% | 5.8% | 5.7% | 5.3% |
| Return on tangible assets | 10.4% | 9.2% | 7.7% | 6.6% | 7.5% | 7.7% | 10.9% | 10.9% | 10.8% | 10.6% |
| Free cash flow margin | 7.4% | 6.7% | 5.6% | 2.8% | 4.1% | 8.3% | 5.0% | 11.5% | 10.5% | 11.1% |
| Income quality (OCF / net income) | 2.08 | 2.20 | 2.42 | 2.60 | 1.74 | 2.48 | 1.77 | 2.61 | 2.42 | 2.45 |
| Financial health | ||||||||||
| Total debt | $2.71B | $2.71B | $2.93B | $2.99B | $3.48B | $3.54B | $3.35B | $2.51B | $2.58B | $3.02B |
| Cash & short-term investments | $145.1M | $85.4M | $141.8M | $21.8M | $49.4M | $224.0M | $94.8M | $69.2M | $54.4M | $40.5M |
| Net debt | $2.57B | $2.63B | $2.79B | $2.97B | $3.43B | $3.32B | $3.25B | $2.45B | $2.52B | $2.98B |
| Debt / equity | 1.11 | 1.31 | 1.78 | 2.28 | 1.82 | 2.23 | 2.48 | 1.89 | 2.18 | 4.10 |
| Debt / assets | 0.38 | 0.42 | 0.48 | 0.53 | 0.51 | 0.55 | 0.55 | 0.48 | 0.53 | 0.64 |
| Net debt / EBITDA | 1.83 | 2.22 | 2.72 | 3.41 | 3.86 | 4.49 | 3.46 | 2.91 | 3.02 | 3.60 |
| Current ratio | 1.08 | 1.05 | 1.28 | 1.25 | 1.23 | 1.32 | 1.05 | 0.98 | 1.36 | 1.38 |
| Quick ratio | 1.08 | 1.05 | 1.17 | 1.19 | 1.14 | 1.23 | 0.97 | 0.90 | 1.24 | 1.25 |
| Interest coverage | 8.5 | 6.3 | 5.1 | 3.6 | 4.0 | 3.6 | 4.3 | 4.6 | 4.2 | 3.8 |
| Working capital | $69.5M | $45.9M | $185.4M | $141.3M | $172.6M | $231.3M | $34.8M | −$10.4M | $184.7M | $178.9M |
| Invested capital | $5.01B | $4.70B | $4.44B | $4.28B | $5.34B | $4.91B | $4.60B | $3.77B | $3.71B | $3.71B |
| Tangible asset value | $1.65B | $1.27B | $737.7M | $316.4M | $1.00B | −$748.4M | −$848.8M | −$673.1M | −$730.2M | −$1.27B |
| Net current asset value | −$2.91B | −$2.80B | −$2.96B | −$3.06B | −$3.54B | −$3.50B | −$3.39B | −$2.69B | −$2.55B | −$2.96B |
| Graham number | $54.53 | $45.05 | $35.66 | $28.15 | $42.02 | $31.93 | $33.23 | $29.62 | $27.04 | $20.35 |
| Graham net-net per share | −$31.35 | −$30.83 | −$31.28 | −$33.21 | −$39.99 | −$37.73 | −$36.73 | −$29.13 | −$28.28 | −$32.27 |
| Capital allocation | ||||||||||
| Dividends paid | $71.1M | $62.8M | $60.4M | $99.0M | $112.4M | $111.9M | $108.7M | $100.8M | $91.5M | $83.8M |
| Share buybacks (net) | $158.0M | $31.1M | $8.2M | $7.3M | $6.1M | $6.1M | $45.9M | $65.6M | $38.1M | $65.6M |
| Dividend payout ratio | 12.6% | 13.8% | 17.2% | 36.5% | 27.3% | 39.4% | 30.3% | 34.5% | 33.8% | 33.8% |
| Dividends + buybacks / free cash flow | 52.2% | 26.1% | 25.6% | 87.3% | 72.0% | 39.8% | 66.9% | 33.8% | 31.4% | 37.1% |
| Capex / revenue | 12.4% | 12.0% | 12.1% | 13.4% | 13.7% | 11.4% | 8.8% | 6.3% | 6.3% | 5.6% |
| Capex / operating cash flow | 62.6% | 64.1% | 68.5% | 82.8% | 77.0% | 57.9% | 63.6% | 35.5% | 37.3% | 33.5% |
| Capex / depreciation | 2.25 | 2.14 | 2.13 | 2.40 | 2.15 | 1.68 | 1.85 | 1.35 | 1.33 | 1.18 |
| Stock-based compensation / revenue | 1.0% | 0.9% | 1.1% | 0.7% | 0.8% | 0.8% | 2.5% | 2.0% | 1.2% | 0.8% |
| SG&A / revenue | 5.0% | 5.0% | 6.5% | 4.8% | 5.7% | 59.4% | 63.0% | 62.0% | 61.3% | 60.1% |
| Efficiency | ||||||||||
| Days sales outstanding | 37.5 | 41.1 | 43.7 | 43.6 | 48.4 | 54.3 | 38.3 | 40.1 | 42.7 | 42.8 |
| Days of inventory on hand | — | — | 6.8 | 6.8 | 10.3 | 131.1 | 126.5 | 139.6 | 150.7 | 139.2 |
| Days payables outstanding | 18.9 | 19.8 | 19.6 | 18.8 | 19.7 | 223.7 | 200.7 | 193.7 | 179.3 | 169.3 |
| Cash conversion cycle (days) | 18.5 | 21.3 | 30.8 | 31.6 | 39.1 | -38.3 | -35.8 | -13.9 | 14.1 | 12.7 |
| Receivables turnover | 9.75 | 8.88 | 8.36 | 8.37 | 7.54 | 6.72 | 9.53 | 9.10 | 8.55 | 8.53 |
| Payables turnover | 19.30 | 18.42 | 18.61 | 19.45 | 18.57 | 1.63 | 1.82 | 1.88 | 2.04 | 2.16 |
| Inventory turnover | — | — | 54.04 | 53.68 | 35.43 | 2.79 | 2.88 | 2.61 | 2.42 | 2.62 |
| Asset turnover | 0.87 | 0.85 | 0.82 | 0.70 | 0.60 | 0.57 | 0.81 | 0.85 | 0.82 | 0.78 |
| Average receivables | $609.0M | $605.2M | $574.2M | $519.5M | $532.5M | $530.9M | $483.2M | $469.9M | $457.9M | $427.1M |
| Average payables | $174.6M | $170.5M | $151.4M | $133.4M | $124.5M | $104.8M | $92.3M | $84.2M | $73.3M | $65.0M |
| Average inventory | — | — | $52.1M | $48.4M | $65.2M | $61.4M | $58.2M | $60.7M | $61.6M | $53.4M |
| Intangibles / total assets | 22.9% | 24.2% | 25.6% | 27.4% | 20.3% | 42.7% | 45.7% | 48.7% | 48.5% | 49.9% |
Computed from EHC's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
EHC valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Encompass Health traded at 19.2 times earnings, against a 10-year median of 18.0. Based on the latest twelve months, the trailing P/E is 21.4 and the forward P/E is 18.9. Encompass Health earned a return on equity of 25.1% and a return on invested capital of 17.3% in fiscal 2025. It ended the year with $2.7 billion of debt and $145.1 million in cash and short-term investments, net debt of $2.6 billion. It returned $229.1 million to shareholders: $71.1 million in dividends and $158.0 million in share buybacks, 52% of free cash flow.
See the EHC income statement, the EHC chart for price history, or the EHC stock overview for the latest quote and news.
EHC key metrics FAQ
What is Encompass Health's P/E ratio?
Encompass Health's trailing P/E ratio is 21.4 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 18.9. At the end of fiscal 2025 it was 19.2, compared with a 10-year median of 18.0.
What is Encompass Health's EV/EBITDA?
Encompass Health's enterprise value was 9.6 times EBITDA at the end of fiscal 2025 (enterprise value $13.4 billion, EBITDA $1.4 billion); the current EV/EBITDA is 9.9.
What is Encompass Health's return on equity?
Encompass Health's return on equity (ROE) was 25.1% in fiscal 2025: net income of $566.2 million on average shareholders' equity of $2.3 billion.
What is Encompass Health's ROIC?
Encompass Health's return on invested capital was 17.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Encompass Health have?
Encompass Health had total debt of $2.7 billion at the end of fiscal 2025, a debt-to-equity ratio of 1.11 and $2.6 billion of net debt (1.83 times EBITDA).
What is Encompass Health's dividend yield?
Encompass Health's forward dividend yield is 0.66%. Encompass Health paid $71.1 million in dividends in fiscal 2025 ($0.70 per share), a payout ratio of 12.6%.
Does Encompass Health buy back its shares?
Yes. Encompass Health spent $158.0 million on net share repurchases in fiscal 2025 Shares outstanding changed 0.0% over the year, to 102.2M..
What is Encompass Health's free cash flow yield?
Encompass Health generated $439.2 million of free cash flow in fiscal 2025, a free cash flow yield of 4.0% on its market value at year-end ($10.8 billion).
What is Encompass Health's current ratio?
Encompass Health's current ratio was 1.08 at the end of fiscal 2025: current assets were 1.08 times current liabilities.